You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Contact a GSK Sales Representative

Chat with Medical Information

Go to Top Close

Invasive Pneumococcal Disease 1

  • IPD is a severe illness that occurs when bacteria invade normally sterile sites, such as the bloodstream or central nervous system.1
  • S. pneumoniae is the primary cause of IPD, which manifests as bacteraemia, bacteraemic pneumonia and meningitis.2
  • IPD can result in serious morbidity and mortality, particularly in children, even in developed countries with high standards of healthcare.2
  • In Canada, overall incidence of IPD in combined age groups has remained steady at approximately 9.0 cases per 100 000 since 2013.3
  • The highest rates of IPD in children occur in infants <1 year of age at 15.51 per 100,000 in 2016.3

Synflorix is not indicated to reduce the morbidity or mortality associated with IPD.

References:

  1. Government of Canada. Canadian Immunization Guide: Part 4. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html. Accessed July 24, 2018.
  2. Synflorix Product Monograph. GlaxoSmithKline Inc. August 31, 2018.
  3. Government of Canada. Notifiable diseases on-line: Invasive pneumococcal disease. Available at: http://diseases.canada.ca/ndis/charts?c=cc. Accessed July 24, 2018.

Français